Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Cardiovascular Outcomes of α-Blockers vs 5-α Reductase Inhibitors for Benign Prostatic Hyperplasia

JAMA Network Open(2023)10.1001/jamanetworkopen.2023.43299Source: DataRank Database

Cardiovascular Outcomes of α-Blockers vs 5-α Reductase Inhibitors for Benign Prostatic Hyperplasia is a research paper published in JAMA Network Open (2023). On theSindex it has a DataRank of 0. It has been cited 15 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access15 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (20 grants)Impact (FWCI 3.74)OA: goldTopics (50)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Chase D. Latour ORCID,Oluwasolape Olawore ORCID,Virginia Pate ORCID,David F. Friedlander ORCID,Til Stürmer‎ORCID

Live enrichment

PubMed:37962887 PMC:PMC10646730 OpenAlex:https://openalex.org/W4388672259

AHRQ HHS

Grant: T32 HS000032

NHLBI NIH HHS

Grant: R01 HL161456

NHLBI NIH HHS

Grant: R01 HL118255

NHLBI NIH HHS

Grant: R01 HL140067

NHLBI NIH HHS

Grant: R01 HL146701

NIMHD NIH HHS

Grant: R01 MD011680

NCI NIH HHS

Grant: R01 CA174453

NHLBI NIH HHS

Grant: R01 HL148432

NIA NIH HHS

Grant: R01 AG056479

NHLBI NIH HHS

Grant: R01 HL165294

National Institutes of Health

Grant: 5R01HL140067-05

Metabolic mechanisms of cardioprotection through alpha-1A adrenergic receptor activation

National Institutes of Health

Grant: 1R01AG056479-01

Propensity scores and preventive drug use in the elderly

National Institutes of Health

Grant: 1R01HL146701-01A1

Targeted treatment of thrombotic occlusions using a dual-delivery microgel therapeutic

National Institutes of Health

Grant: 3T32HS000032-09S1

UNC-CH TRAINING PROGRAM IN HEALTH SERVICES RESEARCH

National Institutes of Health

Grant: 1R01HL118255-01A1

Methods for Estimating Sex Differences in Safety and Effectiveness of Drugs

National Institutes of Health

Grant: 5R01MD011680-04

Racial Differences in Treatment with Hysterectomy: a Multilevel Investigation

National Institutes of Health

Grant: 5R01HL148432-03

PAR1 as a Therapeutic Target in Doxorubicin-induced Cardiotoxicity

National Institutes of Health

Grant: 5R01CA174453-02

PROMIS Validation in Prospective Population-based Prostate Cancer Research Study

National Institutes of Health

Grant: 5R01HL165294-02

Defining the role of mitochondrial injury in MEK inhibitor cardiotoxicity

National Institutes of Health

Grant: 5R01HL161456-04

Engineering a cross-linked cellular network for cardiac repair

FWCI

3.74

Citation Percentile

0.9%

Citation Trend

2024

2025

2026

goldLicense: cc-by

journalhttps://jamanetwork.com/journals/jamanetworkopen/articlepdf/2811818/zhang_2023_oi_231254_1699303111.00695.pdf

publisherhttps://jamanetwork.com/journals/jamanetworkopen/articlepdf/2811818/zhang_2023_oi_231254_1699303111.00695.pdf

journalhttps://doi.org/10.1001/jamanetworkopen.2023.43299

repositoryhttps://pubmed.ncbi.nlm.nih.gov/37962887

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/10646730

Fields of Study

Urinary Bladder and Prostate ResearchSexual function and dysfunction studiesForensic Toxicology and Drug Analysis03 medical and health sciences0302 clinical medicineUnited StatesMaleHumansAged5-alpha Reductase InhibitorsProstatic HyperplasiaCohort StudiesMedicareCardiovascular SystemHeart FailureAdrenergic alpha-Antagonists

MeSH Terms

Adrenergic alpha-AntagonistsAgedCardiovascular SystemMedicareHeart FailureHumansMaleProstatic HyperplasiaUnited StatesCohort Studies5-alpha Reductase Inhibitors

Keywords

MedicineStroke (engine)Internal medicineMyocardial infarctionCohortAdverse effectMaceHeart failureMedical prescriptionCohort studyLower riskPharmacologyMaleProstatic HyperplasiaMedicareCardiovascular SystemUnited StatesCohort Studies5-alpha Reductase InhibitorsHumansAdrenergic alpha-AntagonistsOriginal InvestigationAged

Sustainable Development Goals

SDG 0: Good health and well-being